Inclusion Criteria:  Male or female patients aged from 18 to 70 years old; The patient's ECOG score is ≤ 2; Patients with advanced or metastatic renal cell carcinoma:  (1) have received first-line and second-line targeted therapy in the past; (2) Previous immunization with PD-1/L1 and ≤2 regimens; (3) Unable to tolerate targeted therapy or immunotherapy. 4.There are measurable or evaluable lesions; 5.The main tissues and organs of patients function well:  liver function: ALT/AST< 3 times the upper limit of normal value (ULN); Renal function: creatinine < 220 μmol/L; Lung function: indoor oxygen saturation ≥ 95%; Cardiac function: Left ventricular ejection fraction (LVEF)≥40% 6.Patients or their legal guardians voluntarily participate and sign informed consent.  Exclusion Criteria:  Infectious diseases (such as HIV, active hepatitis B or C infection, active tuberculosis, etc.); Feasibility assessment and screening showed that the transfection of targeted lymphocytes was less than 10% or the amplification was insufficient (< 5 times) under the co-stimulation of CD3/CD28. The vital signs are abnormal, and those who cannot cooperate with the examination; Those who have mental or psychological diseases can not cooperate with treatment and efficacy evaluation; Highly allergic constitution or severe allergic history, especially those who are allergic to IL-2; Subjects with systemic infection or severe local infection who need anti-infection treatment; Complicated with dysfunction of heart, lung, brain, liver, kidney and other important organs; Patients with other tumors; Doctors believe that there are other reasons that can not be included in the treatment.